Purple Biotech (PPBT) Interest Coverage Ratio (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Interest Coverage Ratio of 72.61 for Q1 2026, up 80.76% year-over-year from 40.17 in Q1 2025, and down 33.72% quarter-over-quarter from 109.56 in Q4 2025.
Purple Biotech (PPBT) Interest Coverage Ratio (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Interest Coverage Ratio for 12 consecutive years, with 72.61 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 80.76% year-over-year to 72.61; the TTM figure through Mar 2026 stood at 102.91 (up 543.42% YoY), while the FY2025 annual figure was 27.96, up 22.72% from the prior year.
- Interest Coverage Ratio retreated to 72.61 in Q1 2026 per PPBT's latest filing, from 109.56 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 366.72 in Q4 2022 and bottomed at 14.72 in Q4 2024.
- Historically, Interest Coverage Ratio has averaged 138.74 across 5 years, with a median of 86.81 in 2023.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio tumbled 590.82% — and 2025, when it soared 6449.81%.
- Purple Biotech's Interest Coverage Ratio stood at 366.72 in 2022, then plunged by 99.18% to 3.0 in 2023, then sank by 590.82% to 14.72 in 2024, then surged by 844.06% to 109.56 in 2025, then plunged by 33.72% to 72.61 in 2026.
- Business Quant data shows PPBT's Interest Coverage Ratio at 72.61 in Q1 2026, 109.56 in Q4 2025, and 273.4 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.82 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.08 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.42 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 76.86 |
| 10 | Purple Biotech | 133.62 | 133.62 | - | 144.33 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72.61 |
| Dec 31, 2025 | 109.56 |
| Sep 30, 2025 | 273.40 |
| Jun 30, 2025 | 49.44 |
| Mar 31, 2025 | 40.17 |
| Dec 31, 2024 | -14.72 |
| Sep 30, 2024 | 4.17 |
| Jun 30, 2024 | 144.08 |
| Mar 31, 2024 | 262.71 |
| Dec 31, 2023 | 3.00 |
| Sep 30, 2023 | 359.19 |
| Jun 30, 2023 | 34.70 |
| Mar 31, 2023 | 86.81 |
| Dec 31, 2022 | 366.72 |
| Sep 30, 2022 | 317.56 |
| Jun 30, 2022 | 70.39 |
| Mar 31, 2022 | 178.80 |
| Dec 31, 2021 | 86.46 |
| Sep 30, 2021 | 144.86 |
| Jun 30, 2021 | 35.51 |